Nanoliposomal delivery of cytosolic phospholipase A₂ inhibitor arachidonyl trimethyl ketone for melanoma treatment.

ABSTRACT: Drug resistance and toxicity are major limitations of cancer treatment and frequently occurs during melanoma therapy. Nanotechnology can decrease drug resistance by improving drug delivery, with limited toxicity. This study details the development of nanoparticles containing arachidonyl trifluoromethyl ketone (ATK), a cytosolic phospholipase A₂ inhibitor, which can inhibit multiple key pathways responsible for the development of recurrent resistant disease. Free ATK is toxic, limiting its efficacy as a therapeutic agent. Hence, a novel nanoliposomal delivery system called NanoATK was developed, which loads 61.7% of the compound and was stable at 4^oC for 12 weeks. The formulation decreased toxicity-enabling administration of higher doses, which was more effective at in

SUBMITTER: Gowda R 

PROVIDER: S-EPMC5899023 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature